Blood-Pressure Lowering in Intermediate-Risk Persons without Cardiovascular Disease. - Wikidata - wikimedia - TriplyDB

Blood-Pressure Lowering in Intermediate-Risk Persons without Cardiovascular Disease.

Blood-Pressure Lowering in Intermediate-Risk Persons without Cardiovascular Disease.

http://www.wikidata.org/entity/Q35978709

about

Using Predicted Cardiovascular Disease Risk in Conjunction With Blood Pressure to Guide Antihypertensive Medication Treatment.Stroke Risk Factors, Genetics, and Prevention.Innovative Approaches to Hypertension Control in Low- and Middle-Income Countries.Hypertension Treatment in Blacks: Discussion of the U.S. Clinical Practice Guidelines.Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015.Strengths and Limitations of Using the Polypill in Cardiovascular Prevention.The 2017 Focused Update of the Guidelines of the Taiwan Society of Cardiology (TSOC) and the Taiwan Hypertension Society (THS) for the Management of Hypertension Blood Pressure Management for Stroke Prevention and in Acute Stroke [Management of different cardiovascular risk factors with a combination tablet (polypill)].Comparative Cost-Effectiveness of Conservative or Intensive Blood Pressure Treatment Guidelines in Adults Aged 35-74 Years: The Cardiovascular Disease Policy Model Treatment Intensification for Hypertension in US Ambulatory Medical Care.Blood pressure control in type 2 diabetic patients.7th Brazilian Guideline of Arterial Hypertension: Chapter 5 - Therapeutic Decision and Targets Blood Pressure Targets in the Hypertensive Elderly.Blood pressure control and mortality in US- and foreign-born blacks in New York City.Hypertension up to date: SPRINT to SPYRAL.BP Targets in Hypertension: What Should We Do Now That SPRINT Is Out?Providing innovative solutions in a single pill: Servier's portfolio in hypertension.Role of Coronary Calcium for Risk Stratification and Prognostication.Current Consensus and Controversies in Guidelines for Lipid and Hypertension Management in Diabetes.Estimating Longitudinal Risks and Benefits From Cardiovascular Preventive Therapies Among Medicare Patients: The Million Hearts Longitudinal ASCVD Risk Assessment Tool: A Special Report From the American Heart Association and American College of Car Triple-combination therapy in the treatment of hypertension: a review of the evidence.Ambiguities in the Guidelines for the Management of Arterial Hypertension: Indian Perspective with a Call for Global Harmonization.Treatment of Hypertension: Which Goal for Which Patient?Comparative effectiveness and cost-effectiveness of treat-to-target versus benefit-based tailored treatment of type 2 diabetes in low-income and middle-income countries: a modelling analysis.Wnt signaling, a novel pathway regulating blood pressure? State of the art review.The J-shaped Curve for Blood Pressure and Cardiovascular Disease Risk: Historical Context and Recent Updates.Cost-effectiveness of Intensive Blood Pressure Management.Assessing Cardiovascular Risk to Guide Hypertension Diagnosis and Treatment.Cardiovascular disease prevention strategies for type 2 diabetes mellitus.The Elusive Search for Optimal Blood Pressure Targets.Association Between More Intensive vs Less Intensive Blood Pressure Lowering and Risk of Mortality in Chronic Kidney Disease Stages 3 to 5: A Systematic Review and Meta-analysis.Coronary Artery Calcium to Guide a Personalized Risk-Based Approach to Initiation and Intensification of Antihypertensive Therapy.Proportion and Characteristics of US Adults Who May Be Eligible From Additional Blood Pressure Lowering Based on Absolute Risk.Diastolic Blood Pressure, Subclinical Myocardial Damage, and Cardiac Events: Implications for Blood Pressure Control.Optimal achieved blood pressure for patients with stable coronary artery disease.Lower is better in hypertension, but how low should blood pressure be targeted?Legacy Effect of Delayed Blood Pressure-Lowering Pharmacotherapy in Middle-Aged Individuals Stratified by Absolute Cardiovascular Disease Risk: Protocol for a Systematic Review.The J Curve Phenomenon is Still Valid in the Era of Primary Revascularization Statins alone or polypill for primary prevention of cardiovascular diseases.

P2860

Q30234498-9110CD44-3866-4EAF-BC07-D5C742A1A429 Q30238633-132155EE-975E-4B4B-870A-C7E0CBE45161 Q30240646-9DDA10E7-5543-4869-9988-3A85CAAD6454 Q30244946-B6345F39-0E57-4CCE-91D3-12E781DCF187 Q30353195-C1B6513C-EB41-47CF-8C0D-8B01719706FF Q33581084-547D91EC-8C71-497B-BD8C-48628F7DBA64 Q33729817-3317E872-BA4A-4F3A-AB89-CFBBED6BE2CE Q33783596-40F16D5D-6BBF-4961-AF7A-914641410EFC Q36322893-C14391E3-28C9-4549-B89C-F4C1CBD06CAE Q37265528-680D0682-E323-4E8F-96E5-A09B46036FDA Q37434768-8656E272-C34B-410E-ABE0-346D66378FDD Q37566950-7C99E3BE-D070-41F9-A676-C6CB82FFED72 Q37656167-1273D8D8-6E44-4736-980D-1553722DC432 Q38641512-66A2DE87-A2F5-45F5-B651-40907D8A41B2 Q38691638-BDF1360D-7EA2-4669-A5F6-2A379DC7EF04 Q38741216-4481FBFA-ED42-45BE-81CE-937A2F57CD23 Q38827356-D4B8D9CB-AC7C-418D-86B9-6C3E617B0FC7 Q38833140-68158CE9-B49C-4CED-B5F0-6CE979E10385 Q38919261-F8D9BC18-57BC-4772-AB3A-0A10F45F04BF Q38982216-D8BC612B-1E88-4FAE-BB17-33616A85C17E Q38999152-20318F86-541E-44D9-9526-7DF9A6FF42D8 Q39147724-D5814B82-04DC-41DA-AB7E-7C10972A6ABA Q39148910-F383A144-1EEF-4F51-8379-A832C49B6E5C Q39306446-BF214C28-0A9E-4F82-8B2C-4596C5DF9E87 Q39310857-1828602E-0FDF-4928-9B50-E14F6AE59693 Q39316445-71C27200-6D20-4C75-A2BA-01CB6BBA3D77 Q39371462-CC2EEA6F-65E4-4B8F-A939-EFAD66A1FDF3 Q39390928-F19EE650-88C5-4D83-BD13-54A86CDB4978 Q39413753-3746A154-93C1-4616-B735-9264A1D94D52 Q39420208-1F19662A-C2FE-45DB-B405-48EACB9B15A0 Q39434463-A42CF938-CFAF-4269-BD44-CB4B456A72B4 Q40057422-6A962F82-4B94-4437-BC77-B483191D809F Q40459749-2E359239-A6AA-44B6-80DB-B06B49B23FA7 Q40477905-9D4D14A2-C920-4106-99A5-EB80B49109A2 Q40596645-5B8F6539-D454-42D0-83E0-F18F211C7DD7 Q41580148-1843EFCB-AC8C-47D9-AB1A-0DB038F1D87C Q41665705-C269D9B6-F58D-4B0C-B625-A0024046AC30 Q41686201-9678291D-DCAC-4DA4-B2D9-4312558978E7 Q42340369-5A6CA997-D7AC-4A42-9BA9-8AC279BBE947 Q42356981-DA07B765-DABC-4DF2-9C26-E752F6429759

P2860

Blood-Pressure Lowering in Intermediate-Risk Persons without Cardiovascular Disease.

http://www.wikidata.org/entity/Q35978709

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Blood-Pressure Lowering in Intermediate-Risk Persons without Cardiovascular Disease.

@ast

Blood-Pressure Lowering in Intermediate-Risk Persons without Cardiovascular Disease.

@en

type

label

Blood-Pressure Lowering in Intermediate-Risk Persons without Cardiovascular Disease.

@ast

Blood-Pressure Lowering in Intermediate-Risk Persons without Cardiovascular Disease.

@en

prefLabel

Blood-Pressure Lowering in Intermediate-Risk Persons without Cardiovascular Disease.

@ast

Blood-Pressure Lowering in Intermediate-Risk Persons without Cardiovascular Disease.

@en

P1433

Q35978709-666E920D-37EE-428E-AE37-B12287C6D6EC

P1476

Q35978709-0C59FCF3-1B06-4C4C-8927-D5F00F3D12F7

P2093

Q35978709-03DAD2E1-905C-4A86-B005-D4912F635D59

Q35978709-15A53263-8E40-4C0B-948F-D2F1FB943088

Q35978709-1C46754B-8FC0-4399-81DD-5B83E7C6CF25

Q35978709-1D6D6FAD-3D1E-4EF1-85C8-75ADD380F552

Q35978709-1E02A8F1-D214-42CF-99A6-F414B90831CA

Q35978709-244B0806-8BBE-4CE8-9EDF-0A6496F99666

Q35978709-2E5B53E0-11F2-4A3B-8BA2-02889BF11D70

Q35978709-40676052-C507-42E5-B68E-BD3432A441E4

Q35978709-430F645C-63C5-400B-9517-9D192F3B125B

Q35978709-49F59E02-28A7-4E0F-8620-3173955561B0

P304

Q35978709-AE379B4A-CC71-4F18-BEAD-2C9CB03C034E

P31

Q35978709-29744711-5AB1-4439-97BB-16A72C5710C7

P356

Q35978709-1B9B3153-88DD-4D8C-AED1-F2FFF2880F97

P407

Q35978709-6E78D7F1-0306-4471-91F5-50486E767BE5

P433

Q35978709-C7EFA5CB-C1D4-419F-8392-56E8436990B1

P478

Q35978709-1E71A27D-A3EE-4D00-8816-7497A0940AE4

P50

Q35978709-4C79E4E9-FCF8-4AB5-A00E-9617B0D67A62

Q35978709-5900760D-82C5-46C4-9FB0-5D9428BF6486

Q35978709-78D41407-ED2E-4D97-8D94-BD009F84871D

Q35978709-7BF05356-3777-494C-8E58-61D860D16871

Q35978709-A5288F73-A5BC-4708-AC0B-C141D14142F4

Q35978709-A76CE58D-A820-4770-A246-EE26F887923F

Q35978709-BC2281C8-DF9E-4698-9D22-2D45F3AE991D

Q35978709-C8491B4A-6650-4DBD-8CA3-EBB1532AE840

P577

Q35978709-19EA6DA7-054B-4FA9-9F0D-937E851C3C5F

P698

Q35978709-A5CF9E77-3A2C-4C97-BE4A-AA04CEDB9E3E

P921

Q35978709-F4C6F734-5AE0-4A54-8A3E-65B5D7C90AC2

P356

P1433

The New England Journal of Medicine

P1476

Blood-Pressure Lowering in Intermediate-Risk Persons without Cardiovascular Disease.

@en

P2093

Alexander Parkhomenko

http://www.w3.org/2001/XMLSchema#string

Alvaro Avezum

http://www.w3.org/2001/XMLSchema#string

Antonio Dans

http://www.w3.org/2001/XMLSchema#string

Basil S Lewis

http://www.w3.org/2001/XMLSchema#string

Christopher M Reid

http://www.w3.org/2001/XMLSchema#string

Denis Xavier

http://www.w3.org/2001/XMLSchema#string

Eva M Lonn

http://www.w3.org/2001/XMLSchema#string

HOPE-3 Investigators

http://www.w3.org/2001/XMLSchema#string

Hyejung Jung

http://www.w3.org/2001/XMLSchema#string

Jackie Bosch

http://www.w3.org/2001/XMLSchema#string

P304

2009-2020

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA1600175

http://www.w3.org/2001/XMLSchema#string

P407

P433

21

http://www.w3.org/2001/XMLSchema#string

P478

374

http://www.w3.org/2001/XMLSchema#string

P50

Gilles Dagenais

P577

2016-04-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27041480

http://www.w3.org/2001/XMLSchema#string

P921

cardiovascular disease